Soligenix

Soligenix initiates phase 1 study of SGX203 for pediatric Crohn's disease

Thursday, May 16, 2013 08:00 AM

Soligenix, a clinical stage biopharmaceutical company focused on inflammatory diseases and biodefense countermeasures, has initiated the first clinical study for development of SGX203 (oral beclomethasone 17, 21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease. The program has previously received Fast Track and Orphan Drug designations from the FDA for oral BDP as a treatment for pediatric Crohn's disease.

More... »

Soligenix, Intrexon pursue melioidosis therapy through exclusive collaboration

Friday, May 3, 2013 10:48 AM

Soligenix, a clinical stage biopharmaceutical company focused on inflammatory diseases and biodefense countermeasures, will jointly develop a treatment for melioidosis through a worldwide exclusive collaboration with Intrexon, a synthetic biology company that utilizes its proprietary technologies to provide control over cellular function.

More... »

Soligenix receives IND clearance from FDA for SGX942 in oral mucositis

Wednesday, March 27, 2013 08:59 AM

The FDA cleared the Soligenix’s Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients.

More... »

FDA grants Soligenix Fast Track for OrbeShield for gastrointestinal acute radiation syndrome

Thursday, January 31, 2013 02:00 PM

Soligenix, a development-stage biopharmaceutical company, announced today that its OrbeShield (oral beclomethasone 17, 21-dipropionate or oral BDP) development program for the treatment of gastrointestinal acute radiation syndrome (GI ARS) has received Fast Track designation from the FDA.

More... »

Soligenix acquires novel innate defense regulator clinical program

Tuesday, December 18, 2012 09:44 AM

Soligenix, a Princeton, N.J.-based development stage biopharmaceutical company, has acquired a novel drug technology, known as SGX94, representing a unique approach to modulation of the innate immune system. 

More... »

FDA grants Soligenix Fast Track designation for SGX203 for Crohn's disease

Friday, November 9, 2012 12:44 PM

Soligenix, a development stage biopharmaceutical company based in Princeton, N.J., announced that its drug SGX203, for the treatment of mild-to-moderate pediatric Crohn's disease, has received Fast Track designation from the FDA.

More... »

Soligenix reports positive phase Ib results with Ricin toxin vaccine

Tuesday, September 4, 2012 08:43 AM

Soligenix, a development stage biopharmaceutical company based in Princeton, N.J., released results of a phase Ib trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

More... »

Soligenix, IDRI to develop thermostabilized biodefense vaccines

Wednesday, June 27, 2012 09:44 AM

Soligenix, a development stage biopharmaceutical company, has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, Wash., to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform, ThermoVax. 

More... »

Soligenix demonstrates proof of concept with vaccine technology

Tuesday, February 7, 2012 10:49 AM

Soligenix, a development-stage biopharmaceutical company, has released results from pre-clinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

More... »

Soligenix anthrax vaccine shows robust stability

Sunday, January 22, 2012 11:17 AM

Soligenix, a development-stage biopharmaceutical company, shared results from long-term stability studies of its proprietary DNI (dominant negative inhibitor) anthrax rPA (recombinant protective antigen) subunit protein vaccine, known as SGX204.

More... »